Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
4-1BB agonist antibody treatment induces a population of KLRG1+ T cells that infiltrate
melanoma tumors. We investigated the origin and function of these cells, as well as their …
melanoma tumors. We investigated the origin and function of these cells, as well as their …
[HTML][HTML] 4-1BB: A promising target for cancer immunotherapy
AMJ Kim, MR Nemeth, SO Lim - Frontiers in Oncology, 2022 - frontiersin.org
Immunotherapy, powered by its relative efficacy and safety, has become a prominent
therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer …
therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer …
4-1BB signaling beyond T cells
DS Vinay, BS Kwon - Cellular & molecular immunology, 2011 - nature.com
Originally discovered as a T cell-activating molecule, 4-1BB (CD137) is now also recognized
as an activator of non-T cells, thus imparting a new dimension to its potential in vivo effects …
as an activator of non-T cells, thus imparting a new dimension to its potential in vivo effects …
[HTML][HTML] 4-1BB agonists: multi-potent potentiators of tumor immunity
T Bartkowiak, MA Curran - Frontiers in oncology, 2015 - frontiersin.org
Immunotherapy is a rapidly expanding field of oncology aimed at targeting, not the tumor
itself, but the immune system combating the cancerous lesion. Of the many approaches …
itself, but the immune system combating the cancerous lesion. Of the many approaches …
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal
C Takahashi, RS Mittler, AT Vella - The Journal of Immunology, 1999 - journals.aai.org
After recognition of Ag/MHC and ligation of a costimulatory molecule, resting T cells will
clonally expand and then delete to very low levels. Previously, it was shown that deletion …
clonally expand and then delete to very low levels. Previously, it was shown that deletion …
[HTML][HTML] Limited cross-linking of 4-1BB by 4-1BB ligand and the agonist monoclonal antibody utomilumab
Y Li, S Tan, C Zhang, Y Chai, M He, CWH Zhang… - Cell reports, 2018 - cell.com
Monoclonal antibodies (mAbs) targeting the co-stimulatory molecule 4-1BB are of interest for
tumor immunotherapy. We determined the complex structures of human 4-1BB with 4-1BB …
tumor immunotherapy. We determined the complex structures of human 4-1BB with 4-1BB …
NK1. 1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
I Melero, JV Johnston, WW Shufford, RS Mittler… - Cellular …, 1998 - Elsevier
The 4-1BB (CDw137) T-cell molecule is a member of the TNF receptor family and triggering
by either 4-1BB ligand or antibody ligation induces T-cell activation and growth. We have …
by either 4-1BB ligand or antibody ligation induces T-cell activation and growth. We have …
4-1BB: still in the midst of darkness
1BB is a member of the tumor necrosis factor receptor superfamily. The receptor functions
mainly as a costimulatory molecule in T lymphocytes. In addition, several lines of evidence …
mainly as a costimulatory molecule in T lymphocytes. In addition, several lines of evidence …
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
4-1BB (CD137, tumor necrosis factor receptor superfamily 9) is an inducible costimulatory
receptor expressed on activated T and natural killer (NK) cells. 4-1BB ligation on T cells …
receptor expressed on activated T and natural killer (NK) cells. 4-1BB ligation on T cells …
4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy
JL Cannons, P Lau, B Ghumman… - The Journal of …, 2001 - journals.aai.org
A costimulatory member of the TNFR family, 4-1BB, is expressed on activated T cells.
Although some reports have suggested that 4-1BB is primarily involved in CD8 T cell …
Although some reports have suggested that 4-1BB is primarily involved in CD8 T cell …